InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

Current share price for NOX : $0.065 0.002 (2.99%)+

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$20 New Corporate Presentation 30 May 2017 8:26AM $0.385 $0.065 fallen by 83.12%
$20 St Vincents Cancer Study to Commence-NOX66 and Radiotherapy 29 May 2017 8:21AM $0.360 $0.065 fallen by 81.94%
$20 NOX makes strategic commitment to treatment of rare cancers 24 May 2017 8:50AM $0.380 $0.065 fallen by 82.89%
$20 Noxopharm Mid Year Investor Briefings 18 May 2017 8:27AM $0.290 $0.065 fallen by 77.59%
$20 Market Guidance for Next Six Months 2 May 2017 9:25AM $0.390 $0.065 fallen by 83.33%
$20 Appendix 4C - quarterly 27 Apr 2017 8:29AM $0.375 $0.065 fallen by 82.67%
$20 FNN Interview with NOX CEO Explaining Idronoxil-C Discovery 10 Apr 2017 8:44AM $0.400 $0.065 fallen by 83.75%
$20 NOX Files Patent Application on 'Smart' Idronoxil 10 Apr 2017 8:39AM $0.400 $0.065 fallen by 83.75%
$20 Appendix 3B 3 Apr 2017 8:30AM $0.445 $0.065 fallen by 85.39%
$20 NOX and Monash Uni Collaboration Receives Federal Grant 27 Mar 2017 8:30AM $0.450 $0.065 fallen by 85.56%
$20 Noxopharm and UNSW combine on stroke project 16 Mar 2017 9:24AM $0.435 $0.065 fallen by 85.06%
$20 Gold Coast Qld Mid-Year Briefing Details 10 Mar 2017 8:21AM $0.420 $0.065 fallen by 84.52%
$20 Notification of Release of Restricted Securities Escrow 7 Mar 2017 4:20PM $0.470 $0.065 fallen by 86.17%
$20 NOX researching rare Abscopal Response 3 Mar 2017 10:40AM $0.460 $0.065 fallen by 85.87%
$20 Appendix 4D and Half Year Accounts 24 Feb 2017 5:22PM $0.520 $0.065 fallen by 87.50%
$20 NOX Presentation and Interview ASX The CEO Sessions 24 Feb 2017 12:42AM $0.520 $0.065 fallen by 87.50%
$20 Updated Share Trading Policy 23 Feb 2017 4:19PM $0.510 $0.065 fallen by 87.25%
$20 ASX CEO Presentation Feb 2017 21 Feb 2017 8:21AM $0.555 $0.065 fallen by 88.29%
$20 Upcoming Events and Presentations 15 Feb 2017 8:29AM $0.540 $0.065 fallen by 87.96%
$20 Change of Principal Place of Business 3 Feb 2017 8:26AM $0.500 $0.065 fallen by 87%
$20 Brain Cancer Study Commences 1 Feb 2017 8:32AM $0.500 $0.065 fallen by 87%
$20 First NOX66 Clinical Trial to Commence 31 Jan 2017 10:08AM $0.570 $0.065 fallen by 88.60%
$20 Appendix 4C - quarterly 30 Jan 2017 6:02PM $0.570 $0.065 fallen by 88.60%
$20 Appointment of New Company Secretary 16 Jan 2017 12:02AM $0.510 $0.065 fallen by 87.25%
$20 Appendix 3B 9 Jan 2017 9:49AM $0.460 $0.065 fallen by 85.87%

726 - 750 of 799 results

Page 30 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.